Navigation Links
Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results
Date:3/3/2010

- 3,918 --- --- --- ----- Net income (loss) $5,653 $(56,940) $(6,836) $(184,339) ====== ======== ======= ========= Net income (loss) per share: Basic $0.18 $(2.04) $(0.23) $(7.19) ===== ====== ====== ====== Diluted $0.17 $(2.04) $(0.23) $(7.19) ===== ====== ====== ====== Weighted-average common shares used in computing net income (loss) per share: Basic 31,155 27,948 30,018 25,646 ====== ====== ====== ====== Diluted 33,305 27,948 30,018 25,646 ====== ====== ====== ====== JAZZ PHARMACEUTICALS, INC. SUMMARY OF PRODUCT SALES, NET (In thousands) (Unaudited) Three Months Ended Year Ended December 31, December 31, --------------- ------------- 2009 2008 2009 2008
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
(Date:4/17/2014)... BostonResearchers from Boston University School of Medicine (BUSM) ... alcohol consumption in an experimental model. The findings, ... and Alcohol Abuse , may lead to more ... alcohol is one of the leading causes of ... significant negative economic impact by limiting the productivity ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Elderly People Suffering From CHF, COPD, Diabetes and, ... More Effective With a New, Interactive Telehealth ... NOERRESUNDBY, Denmark, May 19 RTX Healthcare,today announced ... telehealth,monitors, which allows healthcare system integrators and disease ...
... now available in Lexi-Comp(R) ONLINE(TM), providing ... information on diseases and disorders, ... leading,provider of drug reference information, now offers Harrison,s Practice, ... conditions. Harrison,s Practice, developed by McGraw-Hill,Professional, a leading global ...
... United States today are now much more likely to be ... of kidney cancer than a decade ago, leading to a ... national study led by a UC San Diego Medical Center ... UC San Diego Medical Center and the Moores UCSD Cancer ...
... Many patients may soon find relief from the ... bowel syndrome, or IBS. , Lubiprostone, known by the ... Food and Drug Administration for use in women with ... Michigan Health System research that demonstrated the safety and ...
... to advance, device enables deeper enteroscopy, SAN ... ), a leading developer of diagnostic and therapeutic,advancement ... Week 2008 that it has received 510(k) clearance ... with its Endo-Ease Discovery SB,device in endoscopic procedures., ...
... openings avoids incisions, shortens recoveries , , SUNDAY, May ... may lead to painless and scar-free surgery with ... laparoscopic surgery, U.S. studies suggest. , Called ... is inserted through a natural body opening, rather ...
Cached Medicine News:Health News:RTX Healthcare Launch Wireless Telehealth Monitor With Built-in GSM/GPRS Mobile Phone Technology 2Health News:Lexi-Comp, Inc. Offers Diagnosis and Disease Management Tool 2Health News:Lexi-Comp, Inc. Offers Diagnosis and Disease Management Tool 3Health News:Majority of kidney cancers diagnosed at earliest stage 2Health News:Drug brings relief for many IBS patients who experience constipation 2Health News:Spirus Medical Announces 510(k) Clearance from FDA for Expanded Use of Endo-Ease(R) Discovery SB(TM) 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 2Health News:New Surgical Technology Holds Promise of Painless, Scarless Procedures 3
... neurophysiological monitoring system has been designed ... the needs of the ever changing ... collection and analyzing data from multiple ... EMG, EEG and multiple patients at ...
... Inc. is the largest independently ... to ophthalmic surgical instrumentation. Katena ... 7,000 customers in the United ... network of distributors, to customers ...
... Studies have proven that the management of diabetes ... glucose levels is the most effective way to ... care aimed at maintaining or improving a diabetes ... and costly. , ,These have been the ...
... is intended for detecting trends and tracking ... 18 and older) and children/adolescents (aged 7 ... the use of the G2 Biographer with ... to supplement, not replace, conventional blood glucose ...
Medicine Products: